Ripretinib Combined With Surgery in Advanced GIST That Have Failed Imatinib Therapy: A Multicenter,Observational Study

Inclusion Criteria: 1. Patients voluntarily, and signed a written informed consent, good compliance with follow-up; 2. 18 years ≤ age \< 75 years, male or female; 3. Histopathological examination confirmed the diagnosis of recurrent and/or metastatic advanced unresectable gastrointestinal stromal tumor; 4. According to the modified RECISTv1.1-GIST-specific criteria, the subject has at least one measurable lesion; 5. Subjects must have progressed on imatinib or have documented intolerance to imatinib. 6. ECOG PS of ≤ 2, ASA score ≤ 3 at screening; 7. No other malignant tumors occurred within five years; Exclusion Criteria: 1. Molecular pathology report PDGFRA Exon 18 mutation(including D842v); 2. Patients with other serious complications who cannot tolerate surgery: such as severe cardiopulmonary disease, heart function below clinical class 2, pulmonary infection, moderate to severe COPD, chronic bronchitis, severe diabetes and/or renal insufficiency, severe hepatitis and/or Child-pugh class C or B whose symptoms are significantly difficult to correct, severe malnutrition, etc; 3. Pregnant or lactating women; 4. Treatment with any other line of therapy in addition to imatinib for advanced GIST. Imatinib-containing combination therapy in the first-line treatment should not be enrolled. 5. Subject has known active central nervous system metastases. 6. Occurrence of bleeding, perforation, obstruction and other disease-related complications, requiring emergency surgery; 7. The patient has participated in or is participating in other clinical studies , or is taking other TKI agents;